These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 35470044)

  • 1. Short-term obeticholic acid treatment does not impact cholangiopathy in Cyp2c70-deficient mice with a human-like bile acid composition.
    Li R; Hovingh MV; Koehorst M; de Blaauw P; Verkade HJ; de Boer JF; Kuipers F
    Biochim Biophys Acta Mol Cell Biol Lipids; 2022 Aug; 1867(8):159163. PubMed ID: 35470044
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cholangiopathy and Biliary Fibrosis in Cyp2c70-Deficient Mice Are Fully Reversed by Ursodeoxycholic Acid.
    de Boer JF; de Vries HD; Palmiotti A; Li R; Doestzada M; Hoogerland JA; Fu J; La Rose AM; Westerterp M; Mulder NL; Hovingh MV; Koehorst M; Kloosterhuis NJ; Wolters JC; Bloks VW; Haas JT; Dombrowicz D; Staels B; van de Sluis B; Kuipers F
    Cell Mol Gastroenterol Hepatol; 2021; 11(4):1045-1069. PubMed ID: 33309945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gut microbiota depletion aggravates bile acid-induced liver pathology in mice with a human-like bile acid composition.
    Verkade E; Shen W; Hovingh MV; Mulder NL; de Bruyn K; Koehorst M; de Vries HD; Bloks VW; Kuipers F; de Boer JF
    Clin Sci (Lond); 2023 Nov; 137(21):1637-1650. PubMed ID: 37910096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low production of 12α-hydroxylated bile acids prevents hepatic steatosis in Cyp2c70
    Li R; Palmiotti A; de Vries HD; Hovingh MV; Koehorst M; Mulder NL; Zhang Y; Kats K; Bloks VW; Fu J; Verkade HJ; de Boer JF; Kuipers F
    J Lipid Res; 2021; 62():100134. PubMed ID: 34626589
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Perinatal exposure to UDCA prevents neonatal cholestasis in Cyp2c70
    de Vries HD; Palmiotti A; Li R; Hovingh MV; Mulder NL; Koehorst M; Bloks VW; van Zutphen T; Kuipers F; de Boer JF
    Pediatr Res; 2023 May; 93(6):1582-1590. PubMed ID: 36151295
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ileal bile acid transporter inhibition in Cyp2c70 KO mice ameliorates cholestatic liver injury.
    Truong JK; Bennett AL; Klindt C; Donepudi AC; Malla SR; Pachura KJ; Zaufel A; Moustafa T; Dawson PA; Karpen SJ
    J Lipid Res; 2022 Sep; 63(9):100261. PubMed ID: 35934110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A human-like bile acid pool induced by deletion of hepatic
    de Boer JF; Verkade E; Mulder NL; de Vries HD; Huijkman N; Koehorst M; Boer T; Wolters JC; Bloks VW; van de Sluis B; Kuipers F
    J Lipid Res; 2020 Mar; 61(3):291-305. PubMed ID: 31506275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bile Acid Sequestration via Colesevelam Reduces Bile Acid Hydrophobicity and Improves Liver Pathology in
    Palmiotti A; de Vries HD; Hovingh MV; Koehorst M; Mulder NL; Verkade E; Veentjer MK; van Dijk TH; Bloks VW; Havinga R; Verkade HJ; de Boer JF; Kuipers F
    Biomedicines; 2023 Sep; 11(9):. PubMed ID: 37760936
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combining ASBT inhibitor and FGF15 treatments enhances therapeutic efficacy against cholangiopathy in female but not male Cyp2c70 KO mice.
    Hasan MN; Chen J; Matye D; Wang H; Luo W; Gu L; Clayton YD; Du Y; Li T
    J Lipid Res; 2023 Mar; 64(3):100340. PubMed ID: 36737039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation of bile acid metabolism in mouse models with hydrophobic bile acid composition.
    Honda A; Miyazaki T; Iwamoto J; Hirayama T; Morishita Y; Monma T; Ueda H; Mizuno S; Sugiyama F; Takahashi S; Ikegami T
    J Lipid Res; 2020 Jan; 61(1):54-69. PubMed ID: 31645370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative potency of obeticholic acid and natural bile acids on FXR in hepatic and intestinal in vitro cell models.
    Zhang Y; LaCerte C; Kansra S; Jackson JP; Brouwer KR; Edwards JE
    Pharmacol Res Perspect; 2017 Dec; 5(6):. PubMed ID: 29226620
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Obeticholic acid improves hepatic bile acid excretion in patients with primary biliary cholangitis.
    Kjærgaard K; Frisch K; Sørensen M; Munk OL; Hofmann AF; Horsager J; Schacht AC; Erickson M; Shapiro D; Keiding S
    J Hepatol; 2021 Jan; 74(1):58-65. PubMed ID: 32717289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ursodeoxycholic acid is a GPBAR1 agonist and resets liver/intestinal FXR signaling in a model of diet-induced dysbiosis and NASH.
    Carino A; Biagioli M; Marchianò S; Fiorucci C; Zampella A; Monti MC; Scarpelli P; Ricci P; Distrutti E; Fiorucci S
    Biochim Biophys Acta Mol Cell Biol Lipids; 2019 Oct; 1864(10):1422-1437. PubMed ID: 31325638
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glycine-β-Muricholic Acid Improves Liver Fibrosis and Gut Barrier Function by Reducing Bile Acid Pool Size and Hydrophobicity in Male
    Hasan MN; Chen J; Wang H; Du Y; Clayton YD; Gu L; Li T
    Cells; 2023 May; 12(10):. PubMed ID: 37408204
    [No Abstract]   [Full Text] [Related]  

  • 15. Absence of gut microbiota reduces neonatal survival and exacerbates liver disease in Cyp2c70-deficient mice with a human-like bile acid composition.
    Sjöland W; Wahlström A; Makki K; Schöler M; Molinaro A; Olsson L; Greiner TU; Caesar R; de Boer JF; Kuipers F; Bäckhed F; Marschall HU
    Clin Sci (Lond); 2023 Jul; 137(13):995-1011. PubMed ID: 37384590
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Obeticholic acid-a new therapy in PBC and NASH.
    Chapman RW; Lynch KD
    Br Med Bull; 2020 May; 133(1):95-104. PubMed ID: 32282030
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Obeticholic acid may increase the risk of gallstone formation in susceptible patients.
    Al-Dury S; Wahlström A; Panzitt K; Thorell A; Ståhlman M; Trauner M; Fickert P; Bäckhed F; Fändriks L; Wagner M; Marschall HU
    J Hepatol; 2019 Nov; 71(5):986-991. PubMed ID: 31254596
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sex-, age-, and organ-dependent improvement of bile acid hydrophobicity by ursodeoxycholic acid treatment: A study using a mouse model with human-like bile acid composition.
    Ueda H; Honda A; Miyazaki T; Morishita Y; Hirayama T; Iwamoto J; Nakamoto N; Ikegami T
    PLoS One; 2022; 17(7):e0271308. PubMed ID: 35819971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Obeticholic acid improves fetal bile acid profile in a mouse model of gestational hypercholanemia.
    Pataia V; McIlvride S; Papacleovoulou G; Ovadia C; McDonald JAK; Wahlström A; Jansen E; Adorini L; Shapiro D; Marchesi JR; Marschall HU; Williamson C
    Am J Physiol Gastrointest Liver Physiol; 2020 Aug; 319(2):G197-G211. PubMed ID: 32597707
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRD4 inhibition and FXR activation, individually beneficial in cholestasis, are antagonistic in combination.
    Jung H; Chen J; Hu X; Sun H; Wu SY; Chiang CM; Kemper B; Chen LF; Kemper JK
    JCI Insight; 2020 Dec; 6(1):. PubMed ID: 33290278
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.